NVS R&D to Revenue
Novartis AG Common Stock · R&D to Revenue
NVS R&D to Revenue
Latest reported19.60%period ending
NVS FY R&D/Revenue (12.32% → 19.60%)
Latest values, visible window
High-resolution chart · PNG
NVS r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 19.5977% | |
| 19.3767% | |
| 24.3699% | |
| 21.104% | |
| 19.6502% | |
| 17.9967% | |
| 19.3151% | |
| 18.4147% | |
| 19.3277% | |
| 18.2842% | |
| 17.7327% | |
| 16.9407% | |
| 17.2073% | |
| 16.5246% | |
| 16.1398% | |
| 17.5908% | |
| 16.5599% | |
| 16.9477% | |
| 16.5096% | |
| 15.1574% | |
| 16.1227% | |
| 15.2216% | |
| 14.9579% | |
| 13.6179% | |
| 13.474% | |
| 13.0043% | |
| 13.0782% | |
| 12.321% |